Suboptimal use of oral anticoagulants in atrial fibrillation: Has the introduction of direct oral anticoagulants improved prescribing practices?

American Journal of Cardiovascular Drugs

Volumn 16, Issue 3, 2016, Pages 183-200

  Alamneh, Endalkachew A ^a   Chalmers, Leanne ^a   Bereznicki, Luke R ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; XIMELAGATRAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL PRACTICE; EMBASE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICATION COMPLIANCE; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PEER REVIEW; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCOPUS; SYSTEMATIC REVIEW; WEB OF SCIENCE; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; MEDICATION ERROR; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; RISK ASSESSMENT; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION FACTORS; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FACTOR XA INHIBITORS; HUMANS; MEDICATION ERRORS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PYRAZOLES; PYRIDINES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; RIVAROXABAN; STROKE; THIAZOLES; WARFARIN;

EID: 84957677369     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-016-0161-8     Document Type: Review

References (140)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
3. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–51.
4. Freedman JE, Gersh BJ. Atrial fibrillation and stroke prevention in aging patients: what’s good can be even better. Circulation. 2014;130(2):129–31.
5. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014;9(1):113–9.
6. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639–54. doi:10.1038/nrcardio.2014.118.
7. Ball J, Thompson DR, Ski CF, Carrington MJ, Gerber T, Stewart S. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust. 2015;202(1):32–5.
8. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–20.
9. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.
10. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
11. Foley J, Kirchhof P, Lip GY. Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? Curr Vasc Pharmacol. 2014;12(3):373–83.
12. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.
13. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–9. doi:10.1161/01.STR.0000166053.83476.4a.
14. Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15–6. doi:10.1016/j.amjmed.2013.06.002.
15. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.
16. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141(6):757–63. doi:10.1111/j.1365-2141.2008.07119.x.
17. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
18. Bassand JP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace. 2012;14(3):312–24.
19. Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013;61(4):260–6. doi:10.1016/j.jjcc.2012.12.002.
20. Bratland B, Hornnes MB. Warfarin therapy for atrial fibrillation in general practice–is bleeding risk underestimated? Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2014;134(2):175–9. doi:10.4045/tidsskr.13.0626.
21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
22. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106.
23. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938–45.
24. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91. doi:10.1161/circoutcomes.108.796185.
25. Cousins DH, Gerrett D, Warner B. A review of medication incidents reported to the National Reporting and Learning System in England and Wales over 6 years (2005–2010). Br J Clin Pharmacol. 2012;74(4):597–604. doi:10.1111/j.1365-2125.2011.04166.x.
26. Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants. Clevel Clin J Med. 2005;72(Suppl 1):S2–6.
27. Norgard NB, Dinicolantonio JJ, Topping TJ, Wee B. Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Disease. 2012;3(3):123–36.
28. Armaganijan L, Eikelboom J, Healey JS, Morillo CA. New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010. Adv Therapy. 2009;26(12):1058–71.
29. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106(6):997–1011.
30. Odum LE, Cochran KA, Aistrope DS, Snella KA. The CHADS(2) versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. Pharmacotherapy. 2012;32(3):285–96.
31. Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014;44(5):281–90. doi:10.4070/kcj.2014.44.5.281.
32. Dzeshka MS, Lane DA, Lip GY. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol. 2014;37(10):634–44.
33. Lip GY. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J Thromb Haemost. 2013;11(4):615–26. doi:10.1111/jth.12140.
34. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK), Copyright (c) National Clinical Guidelince Center; 2014.
35. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
36. Gamra H, Murin J, Chiang CE, Naditch-Brule L, Brette S, Steg PG. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014;107(2):77–87.
37. Mohammed MA, Marshall T, Nirantharakumar K, Stevens A, Fitzmaurice D. Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. PLoS One. 2013;8(5):e61979.
38. Bednarski J, Cieszewska E, Strzelecki A, Filipiak KJ. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland. Kardiol Pol. 2013;71(12):1260–5.
39. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13–9.e1. doi:10.1016/j.ahj.2011.09.011.
40. Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167(3):329–34. doi:10.1016/j.ahj.2013.12.006.
41. Cullen MW, Kim S, Piccini JP, et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013;6(4):461–9.
42. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.
43. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–30. doi:10.1016/j.cjca.2014.08.001.
44. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27(24):3018–26. doi:10.1093/eurheartj/ehl015.
45. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729–36. doi:10.1016/j.jacc.2005.06.077.
46. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161(20):2458–63.
47. Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011;108(8):1136–40.
48. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166–72.
49. Wang C, Yang Z, Wang C, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157–63. doi:10.1016/j.jstrokecerebrovasdis.2013.10.006.
50. Ogilvie IM, Newton N, Welner SA. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.e4.
51. Piyaskulkaew C, Singh T, Szpunar S, Saravolatz L 2nd, Rosman H. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. J Thromb Thrombolysis. 2014;37(4):400–3. doi:10.1007/s11239-013-0983-z.
52. Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65(14):1385–94.
53. Barnes GD, Kaatz S, Winfield J, et al. Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)). J Thromb Thrombolysis. 2014;37(2):171–6.
54. Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19. doi:10.1093/europace/eut373.
55. Suarez J, Piccini JP, Liang L, et al. International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J. 2012;163(5):804–11.
56. Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123(5):446–53.
57. Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3):229–35.
58. Brandes A, Overgaard M, Plauborg L, et al. Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. Clin Cardiol. 2013;36(7):427–32. doi:10.1002/clc.22133.
59. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010:ehq278.
60. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–31.
61. De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252(11):1316–21. doi:10.1007/s00415-005-0858-0.
62. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.
63. Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129(15):1568–76.
64. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart (British Cardiac Society). 2006;92(8):1064–70.
65. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538–43. doi:10.1016/j.amjcard.2005.09.086.
66. Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther. 2013;35(8):1201–10.
67. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. doi:10.1161/jaha.114.001486.
68. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10(6):674–80. doi:10.1093/europace/eun086.
69. Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75(6):1328–33.
70. Lip G, Bassand J-P, Fitzmaurice D, et al. Inappropriate utilization of anticoagulation in patients with atrial fibrillation: the global anticoagulant registry in the field (garfield) registry. J Am Coll Cardiol. 2012;59(13s1):E670.
71. Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62(603):e710–7. doi:10.3399/bjgp12X656856.
72. Barrios V, Calderon A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl ed). 2012;65(1):47–53. doi:10.1016/j.recesp.2011.08.008.
73. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99(16):1166–72. doi:10.1136/heartjnl-2012-303472.
74. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22. doi:10.2165/0003088-200948010-00001.
75. Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617–33.
76. Haft JI. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants. Clin Applied Thromb Hemost. 2013;19(3):241–8.
77. Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice. Int J Clin Pract. 2013;67(2):139–56. doi:10.1111/ijcp.12023.
78. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–43. doi:10.1161/circulationaha.112.001139.
79. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51. doi:10.1093/europace/eut083.
80. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
81. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
82. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
83. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
84. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi:10.1056/NEJMoa1007432.
85. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41.
86. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–76.
87. Sardar P, Chatterjee S, Lavie CJ, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015;179:279–87.
88. Verdecchia P, Angeli F, Bartolini C, et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. Expert Opin Drug Saf. 2015;14(1):7–20. doi:10.1517/14740338.2014.971009.
89. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–6.e5.
90. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi:10.1016/s0140-6736(13)62343-0.
91. Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J. 2014;12(1):29.
92. Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol. 2014;37(1):32–47.
93. Gonsalves WI, Pruthi RK, Patnaik MM, editors. The new oral anticoagulants in clinical practice. Mayo Clinic Proceedings: Elsevier; 2013.
94. Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79–99.
95. Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther. 2014;39(6):628–36.
96. Mohanty BD, Looser PM, Gokanapudy LR, et al. Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Vasc Med (London, England). 2014;19(3):190–204. doi:10.1177/1358863x14532869.
97. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants. Drugs. 2012;72(13):1739–53.
98. Salem JE, Sabouret P, Funck-Brentano C, Hulot JS. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol. 2015;29(1):10–20. doi:10.1111/fcp.12091.
99. Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ (Clinical research ed). 2014;348:g2116. doi:10.1136/bmj.g2116.
100. Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89. doi:10.1007/s40256-013-0061-0.
101. Arepally GM, Ortel TL. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annu Rev Med. 2015;66:241–53.
102. Bista D, Chalmers L, Bereznicki L, Peterson G. Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol. 2014;70(7):817–28.
103. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306–13.e1.
104. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ open. 2013;1(3):E115–9.
105. Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2(6):e000535.
106. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014. doi:10.1016/j.amjmed.2014.05.013.
107. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9. doi:10.1160/th11-11-0784.
108. Sorea C, Georger F, Makhoul R. 0203: analysis of antithrombotic therapy in patients over 75 years with non-valvular atrial fibrillation: do we apply the guidelines to elderly subjects? Arch Cardiovasc Dis Suppl. 2014;6:4.
109. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–21. doi:10.1161/circoutcomes.112.967299.
110. Biskupiak J, Ghate S, Hamilton M, et al. Oral anticoagulant (OAC) utilization in atrial fibrillation after the introduction of novel oral anticoagulants. J Am Coll Cardiol. 2014;63(12_S). doi:10.1016/S0735-1097(14)60326-0.
111. Shah N, Gosch K, Chan P, Marzec L, Ting H. Use of novel oral anticoagulants for patients with non-valvular atrial fibrillation: results from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;63(12_S). doi:10.1016/S0735-1097(14)60332-6.
112. Gibbs H, Kakkar A. One year Australian outcome results of cohort 1 of the Global Anticoagulant Registry in the FIELD (GARFIELD) study. Heart, Lung Circ. 2013;22:S221-S.
113. Hamilton M, Kawabata H, Liu X, Brixner D, Biskupiak J. Utilization patterns of anticoagulants in non-valvular atrial fibrillation after the entry of novel oral anticoagulants in the United States. Circulation. 2012;126(21 Supplement):A9664.
114. Verdino RJ. Untreated atrial fibrillation in the United States of America: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):44–9.
115. Deitelzweig S. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation. Cardiovasc Ther. 2014;32(2):74–81.
116. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015;115(8):1095–101.
117. Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace: 2015;17(2):187–93. doi:10.1093/europace/euu225.
118. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.
119. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758. doi:10.1136/bmjopen-2013-002758.
120. Gorczyca-Michta I, Wozakowska-Kaplon B. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Kardiol Pol. 2015;73(2):85–93. doi:10.5603/KP.a2014.0168.
121. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015. doi:10.1016/j.amjcard.2015.01.539.
122. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159–64 (discussion 64).
123. Hernandez Olmedo M, Suarez Fernandez C. Progress of anticoagulation therapy in atrial fibrillation. Med Clin. 2014. doi:10.1016/j.medcli.2014.07.018.
124. Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world—a problem or a myth ? Semin Thromb Hemost. 2014;40(8):852–9.
125. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–42.
126. Ebright J, Mousa SA. Oral Anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost. 2015;21(2):105–14. doi:10.1177/1076029614545211.
127. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.
128. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–62.
129. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.
130. Burness CB. Idarucizumab: first global approval. Drugs. 2015;75(18):2155–61. doi:10.1007/s40265-015-0508-5.
131. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.
132. Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective. PharmacoEconomics. 2012;30(2):87–101.
133. Cutler DM, Everett W. Thinking outside the pillbox–medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.
134. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11. doi:10.7326/0003-4819-154-1-201101040-00289.
135. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–70. doi:10.1161/circulationaha.110.985655.
136. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776–85.
137. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.
138. Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies. Thromb Haemost. 2013;110(8):205–12. doi:10.1160/TH13-02-0150.
139. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
140. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109(4):569–79.